PRIA Logo™
119-hr-5629119th CongressWALLET

To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.

Sponsored By: Representative Houchin, Erin [R-IN-9]

Introduced

Summary

Removes most of HHS's 2024 final rule on medications for opioid use disorder but preserves accreditation changes for opioid treatment programs. This bill would void the final rule published at 89 Fed. Reg. 7549 (Feb. 2, 2024) except for the portions that modify Subpart B of Part 8 of Title 42 of the Code of Federal Regulations.

Show full summary
  • People in treatment and families: Accreditation changes for opioid treatment programs remain in place, while the rule's other new policies on medications for opioid use disorder would not apply.
  • Opioid treatment programs and providers: Would need to follow the modified Subpart B accreditation rules but would not be subject to the final rule's other medication-related requirements.
  • HHS and federal regulators: Would be limited to enforcing only the accreditation provisions from 89 Fed. Reg. 7549, with the rest of that final rule vacated.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 0 benefits, 1 costs, 0 mixed.

Cancel opioid treatment rule, keep accreditation

If enacted, this bill would cancel a federal rule on medicines for opioid use disorder (89 Fed. Reg. 7549; Feb 2, 2024). Only the parts about accrediting opioid treatment programs would stay in place. Clinics and doctors would no longer follow the rest of that rule. Patients seeking these medicines could see changed or tighter access. The change would take effect upon enactment.

Sponsors & CoSponsors

Sponsor

Houchin, Erin [R-IN-9]

IN • R

Cosponsors

There are no cosponsors for this bill.

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation